Rentschler Biotechnologie and Rentschler Fill Solutions Team Up

Rentschler Biotechnologie GmbH, a contract development and manufacturing organization (CDMO) for biopharmaceuticals, and Rentschler Fill Solutions GmbH, an independent specialist for aseptic fill and finish services, have formed a strategic partnership to provide new state-of-the-art fill and finish facilities and one-stop solutions for biopharmaceutical products to meet the needs of Rentschler Biotechnologie’s clients.

Rentschler Fill Solutions will prospectively serve as the exclusive partner for the fill and finish services of Rentschler Biotechnologie’s manufacturing projects. Rentschler Fill Solutions is owned by the Rentschler family and will begin operations in mid-2018. In addition to servicing Rentschler Biotechnologie’s clients, Rentschler Fill Solutions will offer its fill and finish services on a clinical as well as commercial scale to its own client base.

"Based on the maturity of the biotech industry and demand for new drugs in growing international markets, we are also seeing more and more demand not only in terms of manufacturing for clinical studies but for commercial-scale manufacturing and market supply. In order to manage the expected growth and provide clients with new, scalable, state-of-the art technologies and facilities, this new partnership with Rentschler Fill Solutions, will allow us to meet today´s and the future needs of our clients," said Frank Mathias, chief executive officer, Rentschler Biotechnologie. "Rentschler Biotechnologie is continually seeking and improving ways to help clients achieve their goals, all along the value chain, from cell line development through finished products. This partnership also supports our recent strategic alliance with Leukocare, as improved formulation strategies will contribute to the quality of the fill and finish process. Both partnerships will enable us to serve our clients as they grow."

At the Rentschler Fill Solutions facility in Austria, state-of-the-art advanced aseptic filling technology will be employed. Vials from DIN2R up to 50 mL can be used for the aseptic filling of liquid or lyophilized biopharmaceuticals in small to medium-sized batches. Up to 60,000 vials per batch can be filled. Timelines and batch sizes can be tailored and flexibly scaled. Standardized and aligned processes and packages enable fast-track services while single-use equipment guarantees maximum product safety. The Rentschler Fill Solutions facility complies with all required regulatory standards and is designed to enable future expansion without interrupting ongoing operations.

"Our state-of-the-art fill and finish facility has been designed to deliver high quality products and reliable services to our clients. As an independent specialist for the aseptic filling of liquid and lyophilized biopharmaceuticals, we aim to manage the specific filling requirements of a wide range of biopharmaceutical companies from clinical studies through market supply," said Reinhold Elsaesser, general manager, Rentschler Fill Solutions. "We very much look forward to working with Rentschler Biotechnologie to address clinical and market needs in terms of capacity, scalability, time to market, purity and safety. The clients of both companies will benefit from reliable one-stop solutions and a fast time to market based on our common commitment to quality and aligned processes."